Nyhetsbyrån Direkt about Cinclus Pharma
ABOUT 80-90% OF THE POTENTIAL FOR LINAPRAZAN GLURATE IN THE US
The research company Cinclus Pharma estimates that approximately 80-90 percent of the potential for the drug candidate Linaprazan Glurate in terms of value lies in the United States. The company's management hopes that Linaprazan Glurate will become a blockbuster, i.e. a drug with annual peak sales of more than one billion dollars. This is what Cinclus Pharma's CEO Christer Ahlberg said during his presentation at Stora Aktiedagarna in Stockholm.